Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eisai to Mobilize All of Its 1,400 MRs to Promote Bendamustine from SymBio
November 8, 2010
- FDA Approves Herceptin for Metastatic Stomach Cancer
November 8, 2010
- DSP: Sales Up 42.6% Due to Addition of Sunovion
November 8, 2010
- Byetta Approved as Japan's 2nd GLP-1 Agonist in Japan: Eli Lilly
November 8, 2010
- Roche Applies for Actemra for sJIA in the US, EU
November 8, 2010
- AZ, Daiichi Sankyo to Copromote Esomeprazole in Japan
November 8, 2010
- Samsca Approved for Excess Water Retention: Otsuka
November 8, 2010
- PhRMA Welcomes Korosho's Vaccine Committee Report
November 8, 2010
- AZ Aims to Add Sales of ¥100 Bil. by 2015
November 8, 2010
- Invega for Schizophrenia, OneDuro Patch for Cancer Pain Approved: Janssen
November 8, 2010
- Shionogi to Jointly Develop New Cephem Antibiotics with GSK
November 8, 2010
- Daiichi Sankyo Wins Levofloxacin Patent Lawsuit in the US
November 8, 2010
- Non-Steroidal Eye Drop Nevanac Approved: Alcon
November 8, 2010
- Group of Clinicians Protests against Asahi Shimbun for Reports on Vaccine Clinical Trial
November 8, 2010
- Shionogi, Sawai Settle Patent Infringement Lawsuit for Flomox
November 8, 2010
- Anti-Histaminic Xyzal Approved: GSK
November 8, 2010
- Chugai Develops New Technology to Produce Reusable MAb
November 8, 2010
- Generics May Save ¥200 Mil. Per Month: Kyokaikenpo
November 8, 2010
- Revolade Approved for ITP: GSK
November 8, 2010
- Chugai Presents Data on Eldecalcitol from Japanese Patients
November 8, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…